Algernon Pharmaceuticals (TSE:AGN) has released an update.
Algernon Pharmaceuticals is set to advance its groundbreaking intravenous DMT stroke research program after successfully divesting its Ifenprodil program to Seyltx. The DMT program, led by Algernon’s subsidiary AGN Neuro, is entering a Phase 2a trial to explore the potential of DMT in promoting neuroplasticity and aiding recovery in ischemic stroke patients without inducing a psychedelic experience. This follows promising results from an earlier Phase 1 trial.
For further insights into TSE:AGN stock, check out TipRanks’ Stock Analysis page.
